

- 1551–4.
4. Roujeau JC et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. *Dermatology* 2004; 209: 301–7.
 5. Gupta AK et al. Onychomycosis in children: prevalence and treatment strategies. *J Am Acad Dermatol* 1997; 36: 395–402.
 6. Vender RB et al. Prevalence and epidemiology of onychomycosis. *J Cutan Med Surg* 2006; 10 (suppl 2): S28–33.
 7. Gupta AK et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. *J Am Acad Dermatol* 2000; 43: 244–8.
 8. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. *Dermatol Ther* 2007; 20: 31–46.
 9. Gupta AK et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. *Br J Dermatol* 1997; 136: 786–9.
 10. Szepletowski JC et al. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. *Arch Dermatol* 2006; 142: 1279–84.
 11. Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. *Clin Exp Dermatol* 1992; 17 (suppl 1): 37–40.
 12. Lecha M et al. Treatment options – development of consensus guidelines. *JEADV* 2005; 19 (suppl 1): 25–33.
 13. Olafsson JH et al. Combination therapy for onychomycosis. *Br J Dermatol* 2003; 149 (suppl 65): 15–8.
 14. Joint Formulary Committee. *British National Formulary*. Edition 54. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, September 2007.
 15. *Lamisil tablets 250mg*. Summary of product characteristics, UK. Novartis Pharmaceuticals UK Limited, February 2007.
 16. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. *BMJ* 1999; 318: 1031–5.
 17. *Sporanox capsules*. Summary of product characteristics, UK. Janssen-Cilag Ltd, March 2004.
 18. *Sporanox-Pulse*. Summary of product characteristics, UK. Janssen-Cilag Ltd, November 2002.
 19. *Loceryl nail lacquer 5%*. Summary of product characteristics, UK. Galderma (UK) Limited, August 2006.
 20. *Curanail 5% nail lacquer*. Summary of product characteristics, UK. Galderma (UK) Limited, August 2006.
 21. *Trosyl nail solution*. Summary of product characteristics, UK. Pfizer Limited, May 2004.
 22. Gupta AK et al. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. *Br J Dermatol* 2004; 150: 537–4.
 23. Warshaw EM et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. *J Am Acad Dermatol* 2005; 53: 578–84.
 24. Gupta AK et al. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. *J Am Acad Dermatol* 2001; 44: 485–91.
 25. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. *Dermatol* 1992; 184 (suppl 1): 21–4.
 26. Tulli A et al. The treatment of onychomycosis with a new form of tioconazole. *Chimioterapia* 1988; 7: 160–3.
 27. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD001434. DOI: 10.1002/14651858.CD001434.pub2 [Date of most substantive amendment: 23 May 2007].
 28. Baran R et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. *Br J Dermatol* 2000; 142: 1177–83.
 29. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. *Br J Dermatol* 2001; 145 (suppl 60): 21–6.
 30. Baran R et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. *Br J Dermatol* 2007; 157: 149–57.
 31. Jennings MB et al. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. *J Am Podiatr Med Assoc* 2006; 96: 465–73.
 32. Seebacher C et al. Onychomycosis. *Mycoses* 2007; 50: 321–7.
 33. Baden HP. Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. *Arch Dermatol* 1994; 130: 558–9.
 34. Hettinger DF, Valinsky MS. Treatment of onychomycosis with nail avulsion and topical ketoconazole. *J Am Podiatr Med Assoc* 1991; 81: 28–32.
 35. Tosti A et al. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. *J Am Acad Dermatol* 2000; 42: 217–24.
 36. Marty J-P et al. Treatment costs of three nail lacquers used in onychomycosis. *J Dermatol Treat* 2005; 16: 299–307.

DTB seeks a deputy editor

DTB is looking for a deputy editor to work for 4 days a week. This permanent position will be advertised this month in the *BMJ* and the *Careers* section of bmj.com. For an informal discussion about this exciting and challenging role, please call Ike Iheanacho, DTB's editor, on +44(0)20 7383 6885.



Editor: Ike Iheanacho BSc, MB BS.

Associate Editors: Helen Barnett BPharm, MSc, LicAc, MBAcc; Paul McManus BSc, DipClinPharm, MRPharmS; Jacoby Patterson MA Cantab, MB BChir, FFPH, MD; Andrea Tarr BPharm, MSc, MRPharmS.

Business Development Manager: Donna Walton BA, MPhil, DipM, ACIM.

Editorial Assistant: Michael Allen BSc.

Contributing Editor: Dr Teck Khong MD, MRCP, St George's University Hospital, London.

Advisory Council:

Martin Duerden B Med Sci, MRCP, Dip Ther, DPH, Conwy Local Health Board and Wales College of Medicine, Cardiff University; Wing May Kong PhD, MRCP, Imperial College & Central Middlesex Hospital, London; Prof. Hywel C. Williams BSc, MSc, FRCP, PhD, University Hospital, Nottingham.

Editorial Board:

Ian Anderson MB BS, MD, MRCP, FRCPsych, University of Manchester & Manchester Mental Health & Social Care Trust; Peter Burrill B Pharm, Dip Pres Sci, MRPharmS, FFPMM, FCPP, Derbyshire County PCT; Ernest H.S. Choy MD, MRCP, GKT School of Medicine, King's College London; Jo Congleton MA, MD, MRCP, Worthing General Hospital; Joanna Girling MA, MBBS, MRCP, FRCOG, West Middlesex University Hospital, London; Aroon Hingorani MA, PhD, FRCP, University College London; Tony Marson MB ChB, MD, FRCP, University of Liverpool & the Walton Centre; Mahdad Noursadeghi MB BS, MRCP, PhD, University College London; George Rylance MB, FRCPCH, Royal Victoria Infirmary, Newcastle upon Tyne; Julia K. Schofield FRCP, West Hertfordshire NHS Hospitals Trust; Harpreet S. Wasan MB BS, FRCP, Imperial College & Hammersmith Hospitals, London.

Editorial correspondence:

DTB, BMJ Group, BMA House, Tavistock Square, London WC1H 9JR, UK
Email: dtb@bmjgroup.com Website: www.dtb.bmj.com



© BMJ Group 2007. Material published in DTB may not be used in any form of advertising, sales or publicity, nor be reproduced without written permission. DTB is commissioned, researched and published by BMJ Group, BMA House, Tavistock Square London WC1H 9JR, UK. Printed by Hobbs the Printers Ltd, Southampton, Hampshire.

Changes of addresses and subscription/distribution enquiries:

All changes of address and orders to DTB, Fulfillment Customer Service, BMJ Group, BMA House, Tavistock Square, London WC1H 9JR, UK. Tel: +44(0)20 7383 6270. Fax: +44(0)20 7383 6402. E-mail: subscriptions@bmjgroup.com.

Annual individual paper subscription £50. For other subscription rates, please email subscriptions@bmjgroup.com for more details. Retired doctors and pharmacists, students £25. Single issues are available—please contact subscriptions@bmjgroup.com for more information.